134 related articles for article (PubMed ID: 28950390)
1. Sphingosine kinase-2 Inhibitor ABC294640 Enhances Doxorubicin-Induced Apoptosis of NSCLC Cells via Altering Survivin Expression.
Hasanifard L; Samadi N; Rashtchizadeh N; Dastmalchi S; Karimi P
Drug Res (Stuttg); 2018 Jan; 68(1):45-53. PubMed ID: 28950390
[TBL] [Abstract][Full Text] [Related]
2. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
[TBL] [Abstract][Full Text] [Related]
3. The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.
Dai L; Smith CD; Foroozesh M; Miele L; Qin Z
Int J Cancer; 2018 May; 142(10):2153-2162. PubMed ID: 29277894
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor.
Guan S; Liu YY; Yan T; Zhou J
Biochem Biophys Res Commun; 2016 Aug; 476(4):230-236. PubMed ID: 27221045
[TBL] [Abstract][Full Text] [Related]
5. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.
Antoon JW; White MD; Slaughter EM; Driver JL; Khalili HS; Elliott S; Smith CD; Burow ME; Beckman BS
Cancer Biol Ther; 2011 Apr; 11(7):678-89. PubMed ID: 21307639
[TBL] [Abstract][Full Text] [Related]
6. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
Zhou J; Chen J; Yu H
Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
[TBL] [Abstract][Full Text] [Related]
7. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.
LeBlanc FR; Pearson JM; Tan SF; Cheon H; Xing JC; Dunton W; Feith DJ; Loughran TP
Br J Haematol; 2020 Aug; 190(3):405-417. PubMed ID: 32124438
[TBL] [Abstract][Full Text] [Related]
10. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640.
White MD; Chan L; Antoon JW; Beckman BS
Anticancer Res; 2013 Sep; 33(9):3573-9. PubMed ID: 24023282
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y
Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609
[TBL] [Abstract][Full Text] [Related]
12. MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells.
Zarogoulidis P; Petanidis S; Kioseoglou E; Domvri K; Anestakis D; Zarogoulidis K
Cell Signal; 2015 Aug; 27(8):1576-88. PubMed ID: 25917317
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
Beljanski V; Lewis CS; Smith CD
Cancer Biol Ther; 2011 Mar; 11(5):524-34. PubMed ID: 21258214
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Induction of Erlotinib-Mediated Apoptosis by Resveratrol in Human Non-Small-Cell Lung Cancer Cells by Down-Regulating Survivin and Up-Regulating PUMA.
Nie P; Hu W; Zhang T; Yang Y; Hou B; Zou Z
Cell Physiol Biochem; 2015; 35(6):2255-71. PubMed ID: 25895606
[TBL] [Abstract][Full Text] [Related]
15. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
Xun C; Chen MB; Qi L; Tie-Ning Z; Peng X; Ning L; Zhi-Xiao C; Li-Wei W
J Exp Clin Cancer Res; 2015 Sep; 34(1):94. PubMed ID: 26337959
[TBL] [Abstract][Full Text] [Related]
16. ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virus-Infected Cell Autophagic Death and Represses Tumor Growth.
Dai L; Bai A; Smith CD; Rodriguez PC; Yu F; Qin Z
Mol Cancer Ther; 2017 Dec; 16(12):2724-2734. PubMed ID: 28939554
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine kinase-2 silencing modulates sensitivity of HT-29 human colorectal cancer cells to paclitaxel-induced cell death through altering apoptosis-related proteins.
Mu Y; Wang J; Li G
Chem Biol Drug Des; 2023 Aug; 102(2):255-261. PubMed ID: 36929215
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival.
Gestaut MM; Antoon JW; Burow ME; Beckman BS
Pharmacol Rep; 2014 Feb; 66(1):174-8. PubMed ID: 24905325
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.
French KJ; Zhuang Y; Maines LW; Gao P; Wang W; Beljanski V; Upson JJ; Green CL; Keller SN; Smith CD
J Pharmacol Exp Ther; 2010 Apr; 333(1):129-39. PubMed ID: 20061445
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin.
Lu C; Shao C; Cobos E; Singh KP; Gao W
PLoS One; 2012; 7(3):e32895. PubMed ID: 22412944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
